logo
Share SHARE
FONT-SIZE Plus   Neg

Genentech Announces "Groundbreaking" Alzheimer's Disease Prevention Trial

Genentech, an unit of Roche Group (RHHBY.PK), said Tuesday it will be part of the first-ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer's disease because of their genetic history.

Genetech said it will collaborate with the National Institutes of Health (NIH), Banner Alzheimer's Institute (BAI), and University of Antioquia in Colombia for the trial.

According to the company, the study - the first to investigate whether an anti-amyloid treatment can stave off the disease - will span two countries and help launch a new era of prevention research in the urgent fight against Alzheimer's.

The company said the $100 million trial is the cornerstone of a new international collaborative, the Alzheimer's Prevention Initiative (API), formed to accelerate the evaluation of promising but unproven prevention therapies.

The trial will probe an experimental anti-amyloid antibody treatment called crenezumab in approximately 300 people from an extraordinarily large extended family in Colombia, who share a rare genetic mutation that typically triggers Alzheimer's symptoms around age 45.

The trial will also include a smaller number of individuals in the U.S. The API team will collaborate with researchers from the NIH-supported Dominantly Inherited Alzheimer's Network (DIAN) to identify and recruit the U.S. participants.

The trial is designed to determine whether the drug can reduce participants' chances of developing the disease's disabling and irreversible symptoms, preserve memory and thinking abilities, and slow the progression of Alzheimer's biomarkers.

The company said that if crenezumab is shown to sustain memory and cognition in people certain to develop Alzheimer's, prevention trials could be designed to test it and other anti-amyloid drugs in a larger segment of the population.

If the treatment's effects on brain imaging and other biological measurements of the disease are shown to predict its clinical benefit, the study could establish a much more rapid way to test future therapies, it added.

According to Roche, about 5.4 million Americans are living with Alzheimer's today, a number expected to top 7.7 million by 2030. Globally, the disease and other dementias are expected to affect nearly 66 million by then.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The U.S. Supreme Court has ruled that basic decorative elements of a cheerleading uniform may be protected by copyright law. The court handed a 6-2 verdict in favor of Varsity Brands Inc., a maker of cheerleader uniforms, in its dispute with smaller rival Star Athletica LLC. Food producer ConAgra Brands Inc. on Thursday updated its fiscal 2017 forecast for adjusted earnings and net sales after reporting lower attributable net income and net sales in its third quarter. Income from continuing operations, however, soared from last year. Sean Connolly, CEO said, "..we are updating our full year guidance to reflect the beneficial timing of certain costs and... Pepsi is pulling large bottles of its products from Philadelphia grocery store shelves after the city's new 1.5-cent-per-ounce tax on sweetened drinks. Its rival Coca-Cola has also been pulling its large bottles, reports said. They are being replaced with smaller bottles and cans of the drinks.
comments powered by Disqus
Follow RTT